516526-45-7

Upstream product

• 516526-44-6 4-(2-fluoro-4-nitro-phenoxy)-6,7-dimethoxy-quinoline 
• 516526-46-8 6-benzyloxy-4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline 
• 516526-43-5 6-(benzyloxy)-4-chloro-7-methoxyquinoline 
• 403-19-0 2-fluoro-4-nitrophenol 

Downstream Products

• 479690-03-4 7-benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methyloxyquinoline 
• 516526-46-8 6-benzyloxy-4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline 
• 1292259-33-6 2-{4-[2-fluoro-4-(2-trifluoromethylbenzenesulfonylamino)phenoxy]-6-methoxyquinolin-7-yloxy}-N,N-dimethylacetamide 
• 1292259-19-8 N-(3-fluoro-4-{7-methoxy-6-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yloxy}phenyl)-2-trifluoromethylbenzenesulfonamide 

Relevant academic research and scientific papers

Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors

The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.

QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

An objective of the present invention is to provide compounds and pharmaceticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, OH, or optionally substituted alkoxy; R4 represents H; R5, R6, R7, and R8 represent H, Hal, alkyl or the like; and R9 represents, e.g., alkyl substituted by t-butyl or the like.